Welcome to our dedicated page for DNA X SEC filings (Ticker: SONM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Sonim Technologies, Inc. (NASDAQ: SONM) provides direct access to the company’s official regulatory disclosures, along with AI-powered tools to help interpret complex documents. These filings trace Sonim’s history as a rugged mobile solutions provider and its transition toward a new business focus on the DNA X decentralized finance trading platform.
Investors can review Form 10-Q and 10-K reports (when available) for detailed discussions of net revenues from phones, wireless internet data devices, accessories, and software, as well as information on operating expenses, liquidity, and risk factors. Quarterly earnings releases are often furnished on Form 8-K, as seen in the October 31, 2025 filing that attaches Sonim’s third quarter 2025 financial results and commentary on product launches and the pending asset sale to NEXA.
Multiple Form 8-K filings document material events central to understanding SONM’s evolution. These include the July 2025 asset purchase agreement with a buyer affiliated with Social Mobile (later referenced as NEXA) to acquire substantially all assets related to Sonim’s enterprise 5G solutions and rugged mobility business; the November 24, 2025 amendment to that agreement; Nasdaq listing notices; and the October 2025 reverse stock split and authorized share increase. A December 18, 2025 Form 8-K details the convertible promissory note with DNA Holdings Venture, Inc. and the membership interest purchase agreement through which Sonim acquired DNA X LLC, a company engaged in the DNAX DeFi on-chain trading protocol.
Registration statements such as the Form S-1 and S-1/A filed in late 2025 describe Sonim’s committed equity facility with Chardan Capital Markets LLC, outlining how the company may sell newly issued common shares over time, the associated risks, and the potential impact on capital structure. The DEF 14A proxy statement for the October 16, 2025 special meeting provides insight into stockholder votes on the reverse stock split, authorized share increase, and related corporate proposals.
On this page, AI-generated summaries can highlight key points from lengthy filings: for example, how a new financing arrangement works, what conditions apply to the NEXA asset sale, or how the DNA X acquisition affects governance and ownership. Users can quickly identify sections related to strategic transactions, listing compliance, equity and debt financing, and the planned rebranding to DNA X, Inc. For those researching insider activity, the platform also surfaces Form 4 insider transaction reports when filed, enabling a consolidated view of executive and director share dealings.
Together, Sonim’s SEC filings and AI explanations offer a structured way to understand the company’s financial position, strategic decisions, and the regulatory steps behind its shift from rugged mobility to a DeFi-oriented crypto trading platform business.
DNA X, Inc. (formerly Sonim Technologies) files its annual report describing its pivot from rugged mobile devices to a crypto trading platform operating at www.dnax.us. The company now focuses on automated cryptocurrency trading, swapping and planned products such as crypto lending and staking-like fee products.
The filing highlights intense competition with much larger exchanges, heavy reliance on third‑party contractors and a highly uncertain, fast‑evolving regulatory landscape for digital assets in the U.S. and abroad. DNA X is not yet profitable, and its auditor raises substantial doubt about its ability to continue as a going concern without additional funding.
The report emphasizes significant risks from cryptocurrency price volatility, potential classification of certain tokens or staking services as securities, and complex privacy, sanctions, consumer protection and anti‑money‑laundering rules. As of June 30, 2025, non‑affiliate equity market value was about $12.6 million, and 1,488,268 common shares were outstanding as of March 27, 2026.
DNA X, Inc. reported full-year 2025 results showing a net loss of $20.7 million, improved from $33.6 million in 2024, with no revenue from continuing operations. Continuing-operations net loss was $8.0 million, driven mainly by $5.4 million in general and administrative expenses and higher interest and other expenses.
The company completed its strategic pivot from mobile devices to cryptocurrency trading. It acquired the DNA X trading platform in December 2025 and sold its mobile device design and manufacturing business to NEXA for $15 million in January 2026. Most proceeds repaid debt and other obligations, with remaining cash earmarked to support the trading business.
As of December 31, 2025, cash and cash equivalents were $1.3 million, total assets $43.9 million, total liabilities $50.6 million, and stockholders’ deficit $8.0 million. The company rebranded to DNA X, Inc., operates a DeFi-based automated trading platform, and experienced leadership changes, including the CEO’s resignation and appointment of its Executive Chairman as acting CEO.
DNA X, Inc. filed an amended current report to clarify the accounting treatment of its acquisition of DNA X LLC. The company had purchased 100% of the membership interests in DNA X LLC for 223,201 shares of its common stock, representing 19.99% of its outstanding common shares at issuance.
After a detailed financial analysis, DNA X determined that this transaction does not involve a “significant amount of assets” for purposes of Item 2.01 of the Exchange Act rules. As a result, the company concluded the transaction did not trigger Item 2.01 disclosure and will not provide the financial statements or pro forma financial information that were referenced in its earlier report.
DNA X, Inc. large shareholder DNA Holdings Venture Inc. filed an initial ownership report showing direct holdings of 223,201 shares of Common Stock. This Form 3 establishes that DNA Holdings Venture Inc. is a more than ten percent owner of DNA X, Inc. as of the reported date.
DNA Holdings Venture Inc., Scott Walker, and Brock Pierce reported a significant stake in DNA X, Inc. on Schedule 13D. They beneficially own 223,201 shares of common stock, representing about 19.99% of DNA X’s outstanding shares based on 1,116,286 shares outstanding as of December 15, 2025.
The stake stems from a membership interest purchase where DNA X acquired 100% of DNA X LLC for 223,201 shares, alongside a $1,200,000 convertible promissory note that is convertible at $5.50 per share starting six months after issuance. DNA Holdings also received a put option tied to DNA X LLC’s trading volume or revenue performance before June 30, 2026.
So long as DNA Holdings owns at least 5% of DNA X’s common stock, it can designate one officer and one board nominee, and it has agreed to vote its shares in favor of a specified asset purchase agreement under an irrevocable proxy through the earlier of January 15, 2026 or that agreement’s termination.
DNA X, Inc. shareholder Laurence W. Lytton filed an amended Schedule 13G reporting a significant passive stake in the company’s common stock. As of the event date, he beneficially owned 148,290 shares, representing 9.96% of the 1,488,268 shares outstanding.
Lytton reports sole voting and dispositive power over 109,402 shares and shared power over 38,888 shares. The filing notes additional warrants to purchase 22,222 shares are excluded because they are subject to a 4.99% beneficial ownership limitation. He certifies the holdings are not intended to change or influence control of DNA X, Inc.
1 Main Capital Management and related reporting persons report that they now beneficially own 0 shares, or 0.0%, of Sonim Technologies common stock as of December 31, 2025. All four reporting entities list zero sole or shared voting and dispositive power over Sonim shares. The filing confirms they own 5 percent or less of the class and certifies the position is not held to change or influence control of Sonim Technologies.
DNA X, Inc. reported that its Chief Financial Officer, Clayton Crolius, received a grant of 35,000 restricted stock units of common stock on February 9, 2026 at a price of $0.00 per share. These units vest in equal monthly installments over one year, conditioned on continued service.
Each restricted stock unit represents the right to receive one share of common stock. After this grant, Crolius beneficially owns 36,719 securities, consisting of 1,719 shares of common stock and 35,000 unvested restricted stock units. The filing notes these figures reflect a 1-for-18 reverse stock split effective October 27, 2025.
DNA X, Inc. Acting CEO and director Michael C. Mulica reported an equity compensation grant. On February 9, 2026, he was awarded 50,000 restricted stock units of common stock at a price of $0.00 per unit as a service-based grant.
The units vest in equal monthly installments over one year, contingent on his continued service. Following this grant, he beneficially owns 54,071 securities, consisting of 4,071 shares of common stock and 50,000 unvested restricted stock units. These figures reflect a 1-for-18 reverse stock split that took effect on October 27, 2025.